HALOZYME THERAPEUTICS, INC. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+51.6% +$154M
$452M
Cost of Revenue↑+87.3% +$37M
$79M
Gross Profit
—
R&D↓-6.5% -$1M
$17M
SG&A↑+82.3% +$35M
$77M
D&A↑+24.5% +$651K
$3M
Operating Income↑+33.5% +$55M
$218M
EBITDA↓-98.1% -$175M
$3M
Interest Expense↑+8.2% +$371K
$5M
Other Income/Expense↓-17.6% -$1M
$5M
Pretax Income↑+32.6% +$54M
$219M
Tax Provision↓-1.1% -$460K
$41M
Net Income↑+27.9% +$38M
$175M
Gross Margin
—
Operating Margin↑+5.3pts
61.5%
Net Margin↑+2.2pts
49.5%
Effective Tax Rate↑+2.9pts
20.0%
Deferred Tax Assets↓-100.0% -$4M
$0
Deferred Tax Liabilities
$35M
Tax Credit Carryforwards
—
ETR (Continuing Operations)↑+11.8pts
32.1%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↑+0.9pts
2.8%
ETR Foreign Differential (pp)↑+0.0pts
0.0%
Operating Lease Cost↑+36.8% +$700K
$3M
Revenue YoY Variation↑+22.0pts
51.6%
Income YoY Variation↓-51.3pts
33.5%
Revenue QoQ Variation↑+24.8pts
27.5%
Income QoQ Variation↓-31.6pts
7.6%